将纳米颗粒转化为病毒“展示盒” 全新疫苗策略可预防致命丝状病毒感染

Core Insights - The Scripps Research Institute has developed a novel vaccine strategy using engineered protein nanoparticles to present viral surface proteins, enhancing the immune system's ability to recognize and respond to filoviruses [1][2] - This new vaccine approach aims to provide broader protection against various deadly filoviruses, including Ebola and Marburg, which currently lack a universal vaccine [1] Group 1: Vaccine Development - The research team has focused on creating a universal vaccine design blueprint for major virus families, enabling rapid response to new virus outbreaks [2] - By employing structure-based rational design, the team has engineered stable and well-defined versions of viral glycoproteins, which are crucial for viral entry into host cells and are primary targets for the immune system [2] - The engineered nanoparticles have successfully induced a broad neutralizing antibody response in mice, laying the groundwork for a more comprehensive filovirus vaccine [2] Group 2: Future Directions - The team is expanding this strategy to other high-risk pathogens such as Lassa virus and Nipah virus, aiming to overcome the glycan shield that hinders immune system attacks on critical viral regions [2] - Despite advancements, the team acknowledges that stabilizing antigens only addresses 60% of the challenges, as dense glycan layers on many viruses remain a significant barrier [2]